Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Assessing Measurable Residual Disease in Mantle Cell Lymphoma
Portfolio Pulse from
Adaptive Biotechnologies has received expanded Medicare coverage for its clonoSEQ assay, which is now approved for assessing measurable residual disease in mantle cell lymphoma patients. This makes clonoSEQ the first and only assay with such coverage, leveraging new Medicare pricing.
November 07, 2024 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adaptive Biotechnologies' clonoSEQ assay has received expanded Medicare coverage for mantle cell lymphoma, potentially increasing its market reach and revenue.
The expanded Medicare coverage for clonoSEQ in mantle cell lymphoma patients is likely to increase the adoption of the assay, potentially boosting Adaptive Biotechnologies' revenue. This development enhances the company's market position in cancer diagnostics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100